|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | Medical College of Wisconsin |
|---|---|
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00002647 |
Purpose
RATIONALE: Photodynamic therapy uses light and photosensitizing drugs to kill tumor cells and may be an effective treatment for refractory brain tumors.
PURPOSE: This phase I trial is studying the side effects and best dose of photodynamic therapy using porfimer sodium in treating patients with refractory brain tumors, including astrocytoma, ependymoma, and medulloblastoma.
| Condition | Intervention | Phase |
|---|---|---|
|
Brain and Central Nervous System Tumors Metastatic Cancer |
Drug: verteporfin Procedure: conventional surgery |
Phase I |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
| Official Title: | Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study |
| Estimated Enrollment: | 24 |
| Study Start Date: | May 1994 |
OBJECTIVES:
OUTLINE: This is a dose-escalation study. Patients are stratified according to tumor location (posterior fossa tumors vs all other brain tumors).
Patients receive benzoporphyrin monoacid ring A (BPD-MA) IV preoperatively. Approximately 3 hours after BPD-MA administration, patients undergo craniotomy with photoillumination of the tumor. Patients with tumors greater than 2 cm in diameter also undergo gross tumor resection.
Cohorts of 3-6 patients receive escalating doses of BPD-MA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose immediately preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Three additional patients are treated at the MTD.
Patients are followed at 4 and 6 weeks, every 3 months for 1 year, every 6 months for 1 year, and then annually thereafter.
PROJECTED ACCRUAL: A minimum of 24 patients will be accrued for this study within 3 years.
Eligibility| Ages Eligible for Study: | 3 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of supratentorial or infratentorial brain tumor
Measurable disease as evidenced by CT scan or MRI
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
Contacts and Locations| United States, Wisconsin | |
| Medical College of Wisconsin Cancer Center | Recruiting |
| Milwaukee, Wisconsin, United States, 53226 | |
| Contact: Clinical Trials Office - Medical College of Wisconsin Cancer C 414-805-4380 | |
| Midwest Children's Cancer Center at Children's Hospital of Wisconsin | Recruiting |
| Milwaukee, Wisconsin, United States, 53226 | |
| Contact: Bruce A. Kaufman, MD 414-266-2000 | |
| Study Chair: | Harry T. Whelan, MD | Medical College of Wisconsin |
More Information
| ClinicalTrials.gov Identifier: | NCT00002647 History of Changes |
| Other Study ID Numbers: | CDR0000064165, MCW-7594, MCW-CHW-511, MCW-CHW-9411, NCI-V95-0652 |
| Study First Received: | November 1, 1999 |
| Last Updated: | January 19, 2012 |
| Health Authority: | Unspecified |
|
recurrent adult brain tumor tumors metastatic to brain recurrent childhood brain stem glioma recurrent childhood anaplastic astrocytoma recurrent childhood anaplastic oligoastrocytoma recurrent childhood anaplastic oligodendroglioma recurrent childhood cerebellar astrocytoma recurrent childhood cerebral astrocytoma recurrent childhood diffuse astrocytoma recurrent childhood fibrillary astrocytoma recurrent childhood gemistocytic astrocytoma recurrent childhood giant cell glioblastoma recurrent childhood glioblastoma recurrent childhood gliomatosis cerebri recurrent childhood gliosarcoma |
recurrent childhood oligodendroglioma recurrent childhood pilocytic astrocytoma recurrent childhood pilomyxoid astrocytoma recurrent childhood pleomorphic xanthoastrocytoma recurrent childhood protoplasmic astrocytoma recurrent childhood subependymal giant cell astrocytoma recurrent childhood visual pathway and hypothalamic glioma recurrent childhood visual pathway glioma recurrent childhood pineoblastoma recurrent childhood supratentorial primitive neuroectodermal tumor recurrent childhood medulloblastoma recurrent childhood ependymoma recurrent childhood brain tumor adult anaplastic astrocytoma adult anaplastic ependymoma |
|
Brain Neoplasms Neoplasm Metastasis Neoplasms Neoplasms, Second Primary Nervous System Neoplasms Central Nervous System Neoplasms Astrocytoma Neoplasms by Site Brain Diseases Central Nervous System Diseases Nervous System Diseases Neoplastic Processes Pathologic Processes Glioma |
Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Verteporfin Photosensitizing Agents Radiation-Sensitizing Agents Physiological Effects of Drugs Pharmacologic Actions Dermatologic Agents Therapeutic Uses |
